The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review*
Abstract
Summary: Background An association between radioiodine therapy (RAI) for Graves’ disease (GD) and the development or worsening of Graves’ ophthalmopathy (GO) is widely quoted but there has been no systematic review of the evidence. Aims We undertook a systematic review of randomized controlled trials (RCTs) to assess whether RAI for GD is associated with increased risk of ophthalmopathy compared with antithyroid drugs (ATDs) or surgery. We also assessed the efficacy of glucocorticoid prophylaxis in the prevention of occurrence or progression of ophthalmopathy, when used with RAI. Methods We identified RCTs regardless of language or publication status by searching six databases and trial registries. Dual, blinded data abstraction and quality assessment were undertaken. Random effects meta‐analyses were used to combine the study data. Ten RCTs involving 1136 patients permitted 13 comparisons. Two RCTs compared RAI with ATD. Two RCTs compared RAI with thyroidectomy. Four RCTs compared the use of adjunctive ATD with RAI vs. RAI. Five RCTs examined the use of glucocorticoid prophylaxis with RAI. Results RAI was associated with an increased risk of ophthalmopathy compared with ATD [relative risk (RR) 4·23; 95% confidence interval (CI): 2·04–8·77] but compared with thyroidectomy, there was no statistically significant increased risk (RR 1·59, 95% CI 0·89–2·81). The risk of severe GO was also increased with RAI compared with ATD (RR 4·35; 95% CI 1·28–14·73). Prednisolone prophylaxis for RAI was highly effective in preventing the progression of GO in patients with pre‐existing GO (RR 0·03; 95% CI 0·00–0·24). The use of adjunctive ATD with RAI was not associated with any significant benefit on the course of GO. Conclusion RAI for GD is associated with a small but definite increased risk of development or worsening of Graves’ ophthalmopathy compared with ATDs. Steroid prophylaxis is beneficial for patients with pre‐existing GO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
Mourits, M. P., Prummel, M. F., Wiersinga, W. M., & Koornneef, L. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2331047.x · Cited by 1,001
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Eckstein, A. K., Plicht, M., Lax, H., Neuhäuser, M., Mann, K., Lederbogen, S., Heckmann, C., Esser, J., & Morgenthaler, N. G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2813 · Cited by 477
Tallstedt, L., Lundell, G., Blomgren, H., & Bring, J. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1300494 · Cited by 171
Abraham-Nordling, M., Törring, O., Hamberger, B., Lundell, G., Tallstedt, L., Calissendorff, J., & Wallin, G. (2005) · Thyroid · doi:10.1089/thy.2005.15.1279 · Cited by 163
Perros, P., Kendall-Taylor, P., Neoh, C., Frewin, S., & Dickinson, J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0507 · Cited by 156
Treatment of Graves' disease and the course of ophthalmopathy
Sridama, V., & DeGroot, L. J. (1989) · The American Journal of Medicine · doi:10.1016/s0002-9343(89)80485-1 · Cited by 137
Cited by
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K., & Pearce, S. H. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 940
De Leo, S., Lee, S. Y., & Braverman, L. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00278-6 · Cited by 883
Bonnema, S. J., & Hegedüs, L. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1030 · Cited by 339
Management of Graves Disease: A Review
Burch, H. B., & Cooper, D. S. (2015) · JAMA · doi:10.1001/jama.2015.16535 · Cited by 332
Metadata
- Authors
- Acharya, S. H., Avenell, A., Philip, S., Burr, J., Bevan, J. S., & Abraham, P.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2008-11-12
- Volume
- 69
- Issue
- 6
- Pages
- 943-950
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2128222543
- Cited by
- 200
- References
- 8
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review*. https://app.cochat.ai/papers/10.1111/j.1365-2265.2008.03279.x
- The paper
- Acharya, S. H., Avenell, A., Philip, S., Burr, J., Bevan, J. S., & Abraham, P. (2008). Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review*. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2008.03279.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.